Filtered By:
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 3967 results found since Jan 2013.
Joint and Soft Tissue Injections
Am Fam Physician. 2023 Aug;108(2):151-158.ABSTRACTJoint and soft tissue injections can be divided into two primary categories: diagnostic and therapeutic. Diagnostic injections facilitate a diagnosis by using a local anesthetic to identify the site of pain or through fluid aspiration for analysis. Therapeutic injections are categorized by the type of injectate and include corticosteroids, hyaluronic acid, dextrose prolotherapy, and platelet-rich plasma. Diagnostic and therapeutic injections are most accurate under direct visualization. Corticosteroid injections help treat adhesive capsulitis and tenosynovitis but are not r...
Source: American Family Physician - August 17, 2023 Category: Primary Care Authors: Julie A Creech-Organ Sarah E Szybist Jacqueline L Yurgil Source Type: research
Hypersensitivity Reactions to Taxanes: A Comprehensive and Systematic Review of the Efficacy and Safety of Desensitization
AbstractTaxanes in the treatment of cancer are associated with a significant incidence of hypersensitivity reactions, which may preclude their use in patients in need of first line therapy. Drug desensitization induces transient immunological tolerance and has allowed the reintroduction of taxanes in highly allergic patients. Increase the knowledge of hypersensitivity reactions (HSR) during the administration of taxanes. A systematic review regarding the safety and efficacy of rapid drug desensitization (RDD) for taxanes HSR. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)...
Source: Clinical Reviews in Allergy and Immunology - August 17, 2023 Category: Allergy & Immunology Source Type: research
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?
Several current guidelines/strategies outline a treatment approach to asthma, which primarily consider the goals of improving lung function and quality of life and reducing symptoms and exacerbations. They suggest a strategy of stepping up or down treatment, depending on the patient's overall current asthma symptom control and future risk of exacerbation. While this stepwise approach is undeniably practical for daily practice, it does not always address the underlying mechanisms of this heterogeneous disease. In the last decade, there have been attempts to improve the treatment of severe asthma, such as the addition of a l...
Source: European Respiratory Journal - August 17, 2023 Category: Respiratory Medicine Authors: Cazzola, M., Page, C. P., Matera, M. G., Rogliani, P., Hanania, N. A. Tags: Asthma and allergy State of the Art Source Type: research
Oral Corticosteroid Reduction Between Biologics Initiated and Non-Initiated Patients with Severe Asthma
Source: Journal of Asthma and Allergy - August 14, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Retrospective Analysis and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
Monoclonal antibodies (MAbs), including omalizumab, mepolizumab, benralizumab and dupilumab revolutionized severe asthma therapy. Each MAb is effective, none clearly superior.1 –3 Nonetheless, many patients switch MAbs due to insufficient response, side effects or to treat comorbidities. Switching MAbs often improves asthma, yet the frequency, causality and outcome of switches remain understudied.4–6 Thus, universal, standardized responder criteria are needed. “Biolo gics Asthma Response Score” (BARS) combines asthma control test, daily oral corticosteroid dose and annualized exacerbation rate, using a scoring syst...
Source: Annals of Allergy, Asthma and Immunology - August 12, 2023 Category: Allergy & Immunology Authors: Moritz Z. Kayser, Ben L. J ülicher, Tobias Welte, Jan Fuge, Hendrik Suhling Tags: Letters Source Type: research
Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
Monoclonal antibodies (MAbs), including omalizumab, mepolizumab, benralizumab, and dupilumab, revolutionized severe asthma therapy. Each MAb is effective, none clearly superior.1 –3 Nonetheless, many patients switch MAbs owing to insufficient response or adverse effects, or to treat comorbidities. Switching MAbs often improves asthma, yet the frequency, causality, and outcome of switches remain understudied.4–6 Thus, universal, standardized responder criteria are needed. “Biologics Asthma Response Score” (BARS) combines asthma control test, daily oral corticosteroid dose, and annualized exacerbation rate, using a s...
Source: Annals of Allergy, Asthma and Immunology - August 12, 2023 Category: Allergy & Immunology Authors: Moritz Z. Kayser, Ben L. J ülicher, Tobias Welte, Jan Fuge, Hendrik Suhling Tags: Letters Source Type: research
